Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor
To the Editor: The recent favorable meta-analysis of
tacrine for treating Alzheimer disease by Dr Qizilbash and
colleagues1 did not consider the potential influence of
corporate sponsorship on the reported studies. Studies without
corporate support found no clinical effect (references 1, 13, 14, 16,
and 21 in the article). All but 1 (reference 24) of the
manufacturer-supported studies found clinical benefit (references 15,
17-20, and 22). We could not locate 1 study (reference 23).
Koepp R, Miles SH. Meta-analysis of Tacrine for Alzheimer Disease: The Influence of Industry Sponsors. JAMA. 1999;281(24):2287–2288. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-24-jbk0623
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: